Toll-like receptor (TLR) 4 is a potent prognostic factor in prostate cancer associated with proliferation and invasion
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Toll-like receptor 4 (TLR4) is linked to prostate cancer progression and aggressiveness. Inhibiting TLR4 with Sparstolonin B reduced cancer cell growth and migration, suggesting TLR4 as a potential therapeutic target.
Area Of Science
- Oncology
- Immunology
Background
- Prostate cancer is a leading male malignancy with unmet needs for novel biomarkers and therapeutic targets.
- Toll-like receptor 4 (TLR4) is implicated in various cancers, but its role in prostate cancer is not well understood.
Purpose Of The Study
- To investigate the clinicopathological significance of TLR4 in prostate cancer.
- To examine the functional role of TLR4 in prostate cancer cell proliferation and migration.
Main Methods
- Immunohistochemical localization of TLR4 in 117 prostate cancer tissues.
- In vitro assays using LNCaP, DU-145, and PC-3 prostate cancer cell lines to assess the effects of TLR4 inhibition by Sparstolonin B (SsnB).
Main Results
- TLR4 was predominantly found in the cytoplasm of prostate cancer cells.
- TLR4 expression positively correlated with proliferation, invasion, and Gleason score.
- SsnB significantly inhibited proliferation and migration in all tested prostate cancer cell lines.
Conclusions
- TLR4 is a significant prognostic factor in prostate cancer, associated with increased proliferation and invasion.
- TLR4 inhibition demonstrates therapeutic potential, suggesting TLR4 as a viable therapeutic target for prostate cancer treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...